| Global Cardiomyopathy Therapies Markets Through 2019-2023; Dominated by AstraZeneca, Merck, Pfizer and Sanofi - ResearchAndMarkets.com |
| Thursday, 10 January 2019 04:06 |
 Jan. 10, 2019 13:47 UTC Global Cardiomyopathy Therapies Markets Through 2019-2023; Dominated by AstraZeneca, Merck, Pfizer and Sanofi - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)-- The "Global Cardiomyopathy Therapies Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The cardiomyopathy therapies market will register a CAGR of almost 2% by 2023. Advent of genomic medicine to push market growth during the forecast period Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual. Initiative to increase awareness about disease There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years. High cost of treatment Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market. Key Players
Topics Covered PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: MARKET LANDSCAPE PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS PART 07: MARKET SEGMENTATION BY TYPE
PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY PRODUCT PART 10: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE PART 14: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/research/t8vxmp/global?w=4 View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005378/en/ Contacts ResearchAndMarkets.com Source: Research and Markets  View this news release online at: "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites            |
Newsletter
